Three ASX stocks built to compound wealth for decades. The post The only 3 ASX blue-chip shares I'd buy and hold until 2036 ...

Die Nvidia GeForce RTX 5060 bietet eine wesentlich höhere Gaming-Performance als die Steam Machine. Ein Gaming-Tower mit ...

Investors have been buying up struggling companies in the hope of a relief rally. But Matthew Brooks says they’re too early ...

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering. The post 3 reasons I'd buy CSL shares in FY27 appeared first on The Motley Fool ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

Business remains robust and brokers see ASX stock soaring up to 100%. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley ...